MedTrace Logo

Japanese BAY86-9766 Monotherapy Phase I Study

NCT01179295 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-06-20

No results posted yet for this study

Summary

This is an uncontrolled, open-label, non-randomized phase I / pharmacokinetic study of oral BAY86-9766 to investigate the safety, tolerability, pharmacokinetics, and efficacy profiles in Japanese patients with advanced solid tumors

Conditions

  • Neoplasms

Interventions

DRUG

BAY86-9766

BAY86-9766 30 mg twice a day (bid).

DRUG

BAY86-9766

BAY86-9766 50 mg twice a day (bid).

DRUG

BAY86-9766

BAY86-9766 100 mg once a day (od)

DRUG

BAY86-9766

BAY86-9766 60 mg once a day (od)

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-19
Primary Completion
2012-04-27
Completion
2012-04-27

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01179295 on ClinicalTrials.gov